Literature DB >> 31591751

Viable pigs after simultaneous inactivation of porcine MHC class I and three xenoreactive antigen genes GGTA1, CMAH and B4GALNT2.

Konrad Fischer1, Beate Rieblinger1, Rabea Hein2, Riccardo Sfriso3, Julia Zuber1, Andrea Fischer1, Bernhard Klinger1, Wei Liang1, Krzysztof Flisikowski1, Mayuko Kurome4, Valeri Zakhartchenko4, Barbara Kessler4, Eckhard Wolf4, Robert Rieben3, Reinhard Schwinzer2, Alexander Kind1, Angelika Schnieke1.   

Abstract

BACKGROUND: Cell surface carbohydrate antigens play a major role in the rejection of porcine xenografts. The most important for human recipients are α-1,3 Gal (Galactose-alpha-1,3-galactose) causing hyperacute rejection, also Neu5Gc (N-glycolylneuraminic acid) and Sd(a) blood group antigens both of which are likely to elicit acute vascular rejection given the known human immune status. Porcine cells with knockouts of the three genes responsible, GGTA1, CMAH and B4GALNT2, revealed minimal xenoreactive antibody binding after incubation with human serum. However, human leucocyte antigen (HLA) antibodies cross-reacted with swine leucocyte antigen class I (SLA-I). We previously demonstrated efficient generation of pigs with multiple xeno-transgenes placed at a single genomic locus. Here we wished to assess whether key xenoreactive antigen genes can be simultaneously inactivated and if combination with the multi-transgenic background further reduces antibody deposition and complement activation.
METHODS: Multiplex CRISPR/Cas9 gene editing and somatic cell nuclear transfer were used to generate pigs carrying functional knockouts of GGTA1, CMAH, B4GALNT2 and SLA class I. Fibroblasts derived from one- to four-fold knockout animals, and from multi-transgenic cells (human CD46, CD55, CD59, HO1 and A20) with the four-fold knockout were used to examine the effects on human IgG and IgM binding or complement activation in vitro.
RESULTS: Pigs were generated carrying four-fold knockouts of important xenoreactive genes. In vitro assays revealed that combination of all four gene knockouts reduced human IgG and IgM binding to porcine kidney cells more effectively than single or double knockouts. The multi-transgenic background combined with GGTA1 knockout alone reduced C3b/c and C4b/c complement activation to such an extent that further knockouts had no significant additional effect.
CONCLUSION: We showed that pigs carrying several xenoprotective transgenes and knockouts of xenoreactive antigens can be readily generated and these modifications will have significant effects on xenograft survival.
© 2019 The Authors. Xenotransplantation published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990B2Mzzm321990; zzm321990B4GALNT2zzm321990; zzm321990CMAHzzm321990; zzm321990GGTA1zzm321990; MHC-I; SLA-I; complement regulators; multiplex CRISPR/Cas9 gene editing; xenotransplantation

Mesh:

Substances:

Year:  2019        PMID: 31591751     DOI: 10.1111/xen.12560

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  29 in total

1.  CRISPR, animals, and FDA oversight: Building a path to success.

Authors:  Laura R Epstein; Stella S Lee; Mayumi F Miller; Heather A Lombardi
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-30       Impact factor: 11.205

2.  Extensively edited pigs.

Authors:  Konrad Fischer; Angelika Schnieke
Journal:  Nat Biomed Eng       Date:  2021-02       Impact factor: 25.671

3.  Immunological and functional features of decellularized xenogeneic heart valves after transplantation into GGTA1-KO pigs.

Authors:  Robert Ramm; Tobias Goecke; Peter Köhler; Igor Tudorache; Serghei Cebotari; Anatol Ciubotaru; Samir Sarikouch; Klaus Höffler; Friederike Bothe; Björn Petersen; Axel Haverich; Heiner Niemann; Andres Hilfiker
Journal:  Regen Biomater       Date:  2021-08-03

Review 4.  Progress in xenotransplantation: overcoming immune barriers.

Authors:  Megan Sykes; David H Sachs
Journal:  Nat Rev Nephrol       Date:  2022-10-05       Impact factor: 42.439

Review 5.  Immune disguise: the mechanisms of Neu5Gc inducing autoimmune and transplant rejection.

Authors:  Fadian Ding; Yunfeng Lin; Guozhong Liu; Yuxin Liu; Feng Gao; Qicai Liu; Zhibo Zhang; Shangeng Weng
Journal:  Genes Immun       Date:  2022-09-23       Impact factor: 4.248

Review 6.  Xenotransplantation: A New Era.

Authors:  Amber N Carrier; Anjali Verma; Muhammad Mohiuddin; Manuel Pascual; Yannick D Muller; Alban Longchamp; Chandra Bhati; Leo H Buhler; Daniel G Maluf; Raphael P H Meier
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

Review 7.  Current Topics of Relevance to the Xenotransplantation of Free Pig Islets.

Authors:  Lisha Mou; Guanghan Shi; David K C Cooper; Ying Lu; Jiao Chen; Shufang Zhu; Jing Deng; Yuanyuan Huang; Yong Ni; Yongqiang Zhan; Zhiming Cai; Zuhui Pu
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 8.786

8.  Extensive germline genome engineering in pigs.

Authors:  Yanan Yue; Weihong Xu; Yinan Kan; Hong-Ye Zhao; Yixuan Zhou; Xiaobin Song; Jiajia Wu; Juan Xiong; Dharmendra Goswami; Meng Yang; Lydia Lamriben; Mengyuan Xu; Qi Zhang; Yu Luo; Jianxiong Guo; Shengyi Mao; Deling Jiao; Tien Dat Nguyen; Zhuo Li; Jacob V Layer; Mailin Li; Violette Paragas; Michele E Youd; Zhongquan Sun; Yuan Ding; Weilin Wang; Hongwei Dou; Lingling Song; Xueqiong Wang; Lei Le; Xin Fang; Haydy George; Ranjith Anand; Shi Yun Wang; William F Westlin; Marc Güell; James Markmann; Wenning Qin; Yangbin Gao; Hong-Jiang Wei; George M Church; Luhan Yang
Journal:  Nat Biomed Eng       Date:  2020-09-21       Impact factor: 25.671

Review 9.  Progress Toward Cardiac Xenotransplantation.

Authors:  Richard N Pierson; Jay A Fishman; Gregory D Lewis; David A D'Alessandro; Margaret R Connolly; Lars Burdorf; Joren C Madsen; Agnes M Azimzadeh
Journal:  Circulation       Date:  2020-10-05       Impact factor: 29.690

Review 10.  Current status of the application of gene editing in pigs.

Authors:  Fuminori Tanihara; Maki Hirata; Takeshige Otoi
Journal:  J Reprod Dev       Date:  2021-04-10       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.